Posted by Michael Wonder on 06 May 2020
Cabaletta Bio receives FDA fast track designation for DSG3-CAART for the treatment of mucosal pemphigus vulgaris
6 May 2020 - Cabaletta Bio today announced that the U.S. FDA has granted fast track designation for DSG3-CAART (Desmoglein 3 chimeric auto-antibody receptor T cells), the Company’s lead product candidate for treatment of mucosal pemphigus vulgaris, for improving healing of mucosal blisters.
DSG3-CAART is designed to specifically target the cause of mucosal pemphigus vulgaris, B cells that express pathogenic auto-antibodies directed against the DSG3 protein, while preserving normal B cell immune function.
The Company plans to initiate its Phase 1 DesCAARTes trial to evaluate the safety and tolerability of DSG3-CAART in relapsed and/or refractory patients in 2020.
